Gmail Calendar Documents Reader Web more »
Help | Sign in
Go to Google Groups Home
   
Discussions for First Solar, Inc. View all discussions
My starred discussions
My profile

  5 Golden Reasons Why VRAL & VGV-1 Drug Will Flourish
Only 1 message in discussion  - 
Reporting discussion
Messages reported
The group you are posting to is a Usenet group. Messages posted to this group will make your email address visible to anyone on the Internet.
Your reply message has not been sent.
Your post was successful
 
From:
To:
Cc:
Followup To:
Add Cc | Add Followup-to | Edit Subject
Subject:
Validation:
For verification purposes please type the characters you see in the picture below or the numbers you hear by clicking the accessibility icon. Listen and type the numbers you hear
 
Gail Wynand  
View profile  
 More options Jul 4, 11:27 pm
From: Gail Wynand <gailwynand...@gmail.com>
Date: Sat, 4 Jul 2009 20:27:16 -0700 (PDT)
Local: Sat, Jul 4 2009 11:27 pm
Subject: 5 Golden Reasons Why VRAL & VGV-1 Drug Will Flourish
Reply to author | Forward | Print | Individual message | Report this message | Find messages by this author
5 Golden Reasons Why VRAL Will Flourish

(1) The CEO of VRAL (Haig Keledjian) is a very passionate scientist,
not a businessman. He has been running VRAL since 1995 and is
certainly not running a fly-by-night operation. He’s in it for the
long term successful completion of FDA approvals for VGV-1.

(2) The VGV-1 drug appears to have other autoimmune applications
including the usage of the drug for treatment of Lyme’s Disease. VRAL
has been awarded two separate grants for the R&D of VGV-1 usage to
treat Lyme’s Disease. Since the mechanism of action involves the
immune system and could potentially treat a variety of autoimmune
diseases, VRAL is pursuing a separate patent for each unique VGV-1
treatment (i.e. one patent for HIV/AIDS treatment, one patent for
Lyme’s Disease treatment, etc) which allows for a number of different
revenue streams moving forward.

(3) The VGV-1 injectable drug has successfully completed Phase 1-3
trials in South Africa for the treatment of HIV/AIDS and has proven
statistically verifiable results that confirm both the drugs safety
and effectiveness in treating the HIV virus. Since Phases 1-3 have
already been completed overseas, one could assume an FDA approval for
the use of VGV-1 would be fast tracked.

4) VRAL has successfully completed 5 clinical trials for the use of
VGV-1 as an HIV/AIDS treatment and has proven statistically
significant results.

5) VRAL scientific advisory team consists of the 2008 Nobel Prize
Winner for Medicine (Dr. Luc Montgainer), a former U.S. Surgeon
General (Dr. C Everett Koop), specialists at Harvard Medical School
(Dr. Eric Rosenberg) and Marshall Phelps, Jr. (Microsoft’s lead IP/
Patent attorney)

VRAL is still in development stages and has yet to file their IND or
begin Phase I trials in the United States (tho they’ve completed
Phases I, II & III overseas). As a long time biotech investor this
tells me two things:
(1) VRAL will not become prosperous overnight, and still has a very
long journey ahead of them.
(2) Becauese they haven’t even filed IND yet, the risk/reward ratio is
at its greatest among all biotech stocks.


    Reply to author    Forward  
You must Sign in before you can post messages.
To post a message you must first join this group.
Please update your nickname on the subscription settings page before posting.
You do not have the permission required to post.

End of messages  

« Newer discussion  -  First Solar president: China has a lot of advantages of solar energy development   QuantaSol the efficiency of solar cells up to 28.3%  -  Older discussion »




Google Home - Terms of Service - Privacy Policy

©2009 Google